One trial ongoing is MIROCALS, which is a phase II study of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuroinflammation in Newly Diagnosed ALS Patients (https://clinicaltrials.gov/study/NCT03039673?a=1). The gene discussed is IL2; the disease is amyotrophic lateral sclerosis.